GSA Capital Partners’s Akero Therapeutics AKRO Stock Holding History

GSA Capital Partners’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,809	Closed	-$323K	–	1635
2025 Q3	$323K	Buy	+6,809	New	+$330K	0.03%	1159
2024 Q2	–	Sell	-11,116	Closed	-$281K	–	1592
2024 Q1	$281K	Buy	+11,116	New	+$267K	0.02%	1254
2023 Q4	–	Sell	-20,597	Closed	-$1.04M	–	1459
2023 Q3	$1.04M	Buy	+20,597	New	+$959K	0.09%	373
2023 Q1	–	Sell	-5,106	Closed	-$280K	–	1446
2022 Q4	$280K	Buy	+5,106	New	+$219K	0.03%	974

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GSA Capital Partners's AKRO Position: Q4 2025 in Review

GSA Capital Partners sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,809 shares — an estimated $323K sold.

GSA Capital Partners first reported a position in AKRO in Q4 2022 and held it in 4 quarters. The position peaked at $1.04M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

GSA Capital Partners reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 6,809 Akero Therapeutics shares in Q4 2025, an estimated $323K.
GSA Capital Partners first reported a position in Akero Therapeutics in Q4 2022 and held it in 4 quarters.
GSA Capital Partners's Akero Therapeutics position peaked at $1.04M in Q3 2023.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.